No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Sichuan Goldstone Asia Pharmaceutical Inc.'s (SZSE:300434) Market Cap Increased by CN¥374m, Insiders Receive a 50% Cut
Sichuan Goldstone (300434.SZ): Yafeng Pharmaceutical Factory has obtained the high-tech enterprise certificate.
Gelonghui, December 31st丨Sichuan Goldstone (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Yafeng Pharmaceutical Co., Ltd. (referred to as "Yafeng Pharmaceutical"), has been recognized as a high-tech enterprise. Recently, Yafeng Pharmaceutical received the "High-Tech Enterprise Certificate" issued jointly by the Zhejiang Provincial Taxation Bureau, Zhejiang Provincial Department of Finance, and Zhejiang Provincial Department of Economy and Information Technology (Certificate No.: GR202433001388, date of issue: December 6, 2024, valid for three years).
Jinshi Asia Pharmaceutical: Report for the third quarter of 2024
Some Shareholders Feeling Restless Over Sichuan Goldstone Asia Pharmaceutical Inc.'s (SZSE:300434) P/S Ratio
Sichuan Goldstone (300434.SZ): Does not involve the production of PBO materials
Goldstone Pharmaceuticals (300434.SZ) stated on the investor interaction platform on September 12 that the company is not involved in the production of PBO materials and is currently conducting research and development work on vacuum coating equipment for the surface metallization treatment of PBO materials.
Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE:300434) Not Doing Enough For Some Investors As Its Shares Slump 26%
